By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Janssen Research & Development 

3210 Merryfield Row

San Diego  California  92121  U.S.A.
Phone: 858-450-2000 Fax: n/a

At Janssen Research & Development, LLC, we are united and energized by one mission – to discover and develop innovative medicines that ease patients' suffering, and solve the most important unmet medical needs of our time.

As one of the Janssen Pharmaceutical Companies, our strategy is to identify the biggest unmet medical needs and match them with the best science, internal or external, to find solutions for patients worldwide. We leverage our world-class discovery and development expertise, and operational excellence, to bring innovative, effective treatments in five therapeutic areas:

• cardiovascular and metabolism,
• immunology,
• infectious diseases and vaccines,
• neuroscience, and
• oncology.

We think of the world as our laboratory and we look for innovation wherever it exists. This drives our relentless search for the best science, and our pursuit of collaborations and partnerships.

We believe there are no limits to what science can do. And we never lose sight of those who rely most on our discoveries.


Janssen Labs is part of Johnson & Johnson’s external research and development engine and provides a capital-efficient, resource-rich environment where independent emerging companies can progress their research.
The 30,000 square foot flagship facility opened in early 2012 in San Diego at Janssen’s West Coast Research Center and currently hosts 30 emerging life science companies. Janssen Labs offers singular bench tops, modular wet lab units and office space on a short-term basis, allowing companies to pay only for the space they need, with an option to quickly expand when they have the resources to do so. Janssen Labs is an open innovation model, and the agreement for space does not grant Janssen any stake in the companies, nor will the companies have a guaranteed future affiliation with Janssen; but the models is designed to initiate a dialogue early and foster long term relationships with innovators in healthcare.

Key Statistics

Ownership: Private

Web Site: Janssen Research & Development


Company News
Janssen Research & Development Release: New Long-Term Data Show INVOKANA® (canagliflozin) Lowers Blood Glucose In Older Patients With Type 2 Diabetes Inadequately Controlled On Other Therapies 6/17/2014 10:02:54 AM
GlaxoSmithKline (GSK)'s ViiV Healthcare Joins Johnson & Johnson (JNJ)'s Janssen Research & Development To Develop Single-Pill HIV Drug 6/12/2014 6:50:49 AM
Janssen Research & Development To Present Latest Data For Type 2 Diabetes Treatment INVOKANA® (canagliflozin) At American Diabetes Association 74th Scientific Sessions® 6/10/2014 9:33:59 AM
Janssen Research & Development To Showcase Growing Body Of Data At 2014 American Society of Clinical Oncology Annual Meeting 5/15/2014 6:57:54 AM
Janssen Research & Development Submits Supplemental New Drug Application To FDA For OLYSIO™ (Simeprevir) For Once-Daily Use In Combination With Sofosbuvir For 12 Weeks For The Treatment Of Adult Patients With Genotype 1 Chronic Hepatitis C 5/7/2014 9:22:18 AM
Final Data From The Phase 2 COSMOS Study Of Janssen Research & Development's Once-Daily Simeprevir In Combination With Sofosbuvir Presented At The International Liver Congress™ 2014 Of The European Association For The Study Of The Liver (EASL) 4/14/2014 6:33:02 AM
Janssen Research & Development Release: Supplemental New Drug Application For IMBRUVICA™ (ibrutinib) Submitted To The U.S. FDA 4/8/2014 9:13:05 AM
Janssen Research & Development Submits New Drug Application To FDA For A Fixed-Dose Combination Tablet Of HIV-1 Medicine Darunavir With Cobicistat As Part Of Combination HIV Therapy 4/2/2014 11:20:18 AM
Johnson & Johnson (JNJ)'s Janssen Research & Development Test of Schizophrenia Treatment Shows Positive Results 3/20/2014 7:04:52 AM
Novozymes Biopharma Announces Collaboration With Janssen Research & Development To Evaluate Proprietary VELTIS® Half-Life Extension Technology 3/13/2014 9:43:34 AM